Physician profile
Keith Delong
NPI 1629406863
$8,721.71
in general payments reported to CMS, 2019-2025
24 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $314 · 2023: $1,283 · 2024: $5,213 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,586 · Consulting Fee: $2,310 · Travel and Lodging: $1,664 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,586.44 |
| Consulting Fee | $2,310.00 |
| Travel and Lodging | $1,664.11 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,780.62 | 2021-2025 | Epclusa, Descovy, Biktarvy |
| Viiv Healthcare Company | $1,204.90 | 2021-2025 | Apretude, Dovato, Rukobia |
| Janssen Products, LP | $483.19 | 2021 | |
| Merck Sharp & Dohme LLC | $238.09 | 2023-2025 | Delstrigo, Pifeltro, Dificid |
| Lilly USA, LLC | $134.81 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $128.43 | 2023-2025 | |
| Janssen Biotech, INC. | $118.91 | 2021-2023 | Symtuza |
| Exact Sciences Corporation | $78.40 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $67.08 | 2024-2025 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $57.59 | 2024-2025 | Auvelity |
| Pfizer INC. | $56.32 | 2023-2025 | |
| Emd Serono, INC. | $47.89 | 2025 | |
| Napo Pharmaceuticals INC | $44.50 | 2025 | Mytesi |
| Novo Nordisk INC | $44.42 | 2023-2025 | Wegovy |
| Verity Pharmaceuticals INC. | $36.81 | 2025 | Tlando |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $34.66 | 2023 | Nexplanon |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.36 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $20.96 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Vertex Pharmaceuticals Incorporated | $20.63 | 2024 | |
| Coopersurgical, INC. | $17.81 | 2023 | Paragard T 380a |
| Theratechnologies INC. | $17.37 | 2025 | Trogarzo, Egrifta |
| Biohaven Pharmaceutical Holding Company LTD. | $16.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.50 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Delong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.